UBS Group
RUBY

UBS Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

UBS Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-72,662
Closed -$13.1K – 11342
2022
Q4 		$13.1K Buy
72,662
+60,676
+506% +$16.6K ﹤0.01% 8202
2022
Q3 		$5K Buy
+11,986
New +$8.98K ﹤0.01% 9288
2022
Q2 		– Sell
-522
Closed -$3K – 11444
2022
Q1 		$3K Sell
522
-105,682
-100% -$671K ﹤0.01% 9558
2021
Q4 		$1.03M Buy
106,204
+24,734
+30% +$343K ﹤0.01% 4374
2021
Q3 		$1.46M Buy
81,470
+71,837
+746% +$1.56M ﹤0.01% 3858
2021
Q2 		$235K Sell
9,633
-1,478
-13% -$37K ﹤0.01% 5238
2021
Q1 		$294K Buy
11,111
+8,231
+286% +$120K ﹤0.01% 5215
2020
Q4 		$22K Buy
2,880
+1,880
+188% +$11.2K ﹤0.01% 6890
2020
Q3 		$5K Sell
1,000
-1,288
-56% -$6.82K ﹤0.01% 7358
2020
Q2 		$14K Sell
2,288
-10,426
-82% -$61.5K ﹤0.01% 6807
2020
Q1 		$56K Sell
12,714
-24,508
-66% -$182K ﹤0.01% 5749
2019
Q4 		$354K Buy
37,222
+27,261
+274% +$264K ﹤0.01% 5150
2019
Q3 		$78K Buy
+9,961
New +$116K ﹤0.01% 5916
2019
Q2 		– Sell
-23
Closed – – 8275
2019
Q1 		$0 Buy
+23
New +$353 ﹤0.01% 8330
2018
Q4 		– Sell
-2,868
Closed -$69K – 8418
2018
Q3 		$69K Buy
+2,868
New +$65.6K ﹤0.01% 5903

Other funds holding RUBY

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return

UBS Group's RUBY Position: Q1 2023 in Review

UBS Group sold out of Rubius Therapeutics, Inc (RUBY) in Q1 2023, closing a stake of 72,662 shares — an estimated $13.1K sold.

UBS Group first reported a position in RUBY in Q3 2018 and held it in 15 quarters. The position peaked at $1.46M in Q3 2021. 7 funds tracked by Wall St. Rank hold RUBY as of Q1 2023.

  • UBS Group reported no remaining Rubius Therapeutics, Inc position as of Q1 2023 after selling out during the quarter.
  • UBS Group sold 72,662 Rubius Therapeutics, Inc shares in Q1 2023, an estimated $13.1K.
  • UBS Group first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 15 quarters.
  • UBS Group's Rubius Therapeutics, Inc position peaked at $1.46M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.